ABSTRACT
Aim: The programmed death 1 (PD-1) / PD-ligand (PDL) pathway is an important checkpoint for regulation of T cell mediated immune responses. Malignancies unfortunately also benefit from the immunosuppressive effects of the PD-1/PD-L1 pathway. There is not enough evidence regarding the importance of PD-1/ PD-L1 in Diffuse large B cell lymphoma (DLBCL) and Chronic lymphocytic leukemia (CLL). We aimed to evaluate the presence and prognostic significance of PD-1 / PD-L1 expression in DLBCL and CLL. Materials and Methods: 26 DLBCL patients and 27 CLL patients aged between 18-80 years, who were followed up between January 2010 and September 2018 in Hematology Clinic, were included. For immunohistochemical staining, paraffin blocks belonging to the patients in the archive of Medical Pathology Department were used. Lymph node biopsy materials of DLBCL patients and bone marrow biopsy materials of CLL patients were evaluated. PD-1 was stained in non-neoplastic tissues and PD-L1 was stained in neoplastic cells. Those whose staining percentage was above 5% were considered positive. Results: PD-1; It was detected positive in 65.4% (n=17) of DLBCL cases and 14.8% (n=4) of CLL cases. PD-L1 was detected positive in 69.2% (n=18) of DLBCL cases, and PD-L1 was positive in 3.7% (n=1) of CLL cases. The frequency of PD-1 and PD-L1 expression and staining was found to be statistically significantly higher in DLBCL (p=<0.001). In PD-L1, a significant difference in expression was found between stages only in cases diagnosed with DLBCL (P=0,004). Conclusion: In our study, a higher rate of PD-1/ PD-L1 expression was detected in DLBCL than in the literature. A lower rate of PD-1/ PD-L1 expression was detected in CLL compared to other studies. It has been shown that PD-1/ PD-L1 expression is higher in DLBCL than in CLL. Keywords: Diffuse large B cell lymphoma, Chronic lymphocytic leukemia, PD-1, PD-L1.
Cite this Article As :
Akkus C, Demircioglu S, Erten R, Cetin Dagli S, Dogan A. Evaluation of PD-1/PD-L1 Expressions in Patients with Diffuse Large B Cell Lymphoma and Chronic Lymphocytic Leukemia. Selcuk Med J 2024;40(2): 82-87
Keir ME, Butte MJ, Freeman GJ, et al.: PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol 2008; 26:677–704
2. Kaufman HL, Russell J, Hamid O, et al.: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016; 17:1374–1385
3. Ou J-N, Wiedeman AE, Stevens AM: TNF-α and TGF-β Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus. Sci Rep 2012; 2:295
4. Nishimura H, Nose M, Hiai H, et al.: Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor. Immunity 1999; 11:141–151
5. Fife BT, Pauken KE: The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci 2011; 1217:45–59
6. West EE, Youngblood B, Tan WG, et al.: Tight Regulation of Memory CD8+ T Cells Limits Their Effectiveness during Sustained High Viral Load. Immunity 2011; 35:285–298
7. Weber J: Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade. Semin Oncol 2010; 37:430–439
8. Muenst S, Soysal SD, Tzankov A, et al.: The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets 2015; 19:201–211
9. Younes A, Santoro A, Shipp M, et al.: Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17:1283–1294
10. Yang J, Hu G: Significance of PD L1 in the diagnosis and treatment of B cell malignant lymphoma. Oncol Lett 2019;
11. Kiyasu J, Miyoshi H, Hirata A, et al.: Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 2015; 126:2193–2201
12. Zhang W, Bai J, Zuo M, et al.: PD‐1 expression on the surface of peripheral blood CD4 + T cell and its association with the prognosis of patients with diffuse large B‐cell lymphoma. Cancer Med 2016; 5:3077–3084
13. Kwon D, Kim S, Kim P-J, et al.: Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology 2016; 68:1079–1089
14. Chen BJ, Chapuy B, Ouyang J, et al.: PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research 2013; 19:3462–3473
15. Xing W, Dresser K, Zhang R, et al.: PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 2016; 7:59976–59986
16. Li L, Zhang J, Chen J, et al.: B-cell receptor–mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood 2018; 132:1805–1817
17. Menter T, Bodmer-Haecki A, Dirnhofer S, et al.: Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol 2016; 54:17–24
18. Gassner FJ, Zaborsky N, Catakovic K, et al.: Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model. Br J Haematol 2015; 170:515–22
19. Grzywnowicz M, Zaleska J, Mertens D, et al.: Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia. PLoS One 2012; 7:e35178
20. Li JH, Pang NN, Zhang ZH, et al.: [PD-1/PD-L1 expression and its implications in patients with chronic lymphocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:198–203
21. Gamaleldin MA, Ghallab OM, Nadwan EA, et al.: PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia. Clinical and Translational Oncology 2021; 23:2309–2322
22. Lesokhin AM, Ansell SM, Armand P, et al.: Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology 2016; 34:2698–2704
Keywords